How to Analyze Therapy in the Medical Literature (part 2)

Slides:



Advertisements
Similar presentations
Appraisal of an RCT using a critical appraisal checklist
Advertisements

SHARP trial Study of Heart and Renal Protection : a randomised placebo-controlled trial The e ff ects of lowering LDL cholesterol with simvastatin plus.
Reporting drugs and treatments Thomas Abraham. What we will learn today The difference between absolute and relative risk reduction A basic way to interpret.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2014.
Critical Appraisal of Systematic Reviews Douglas Newberry.
CRITICAL APPRAISAL Dr. Cristina Ana Stoian Resident Journal Club
Critical Appraisal of an Article on Therapy. Why critical appraisal? Why therapy?
Critical Appraisal for MRCGP Jim McMorran Coventry GP GP trainer Editor GPnotebook (
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
Obstructive Sleep Apnea
Critical Appraisal of an Article on Therapy (2). Formulate Clinical Question Patient/ population Intervention Comparison Outcome (s) Women with IBS Alosetron.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
The Bahrain Branch of the UK Cochrane Centre In Collaboration with Reyada Training & Management Consultancy, Dubai-UAE Cochrane Collaboration and Systematic.
JAMA: Users’ guide to evidence-based medicine
DEB BYNUM, MD AUGUST 2010 Evidence Based Medicine: Review of the basics.
CAT 2: Therapy Maribeth Chitkara, MD Rachel Boykan, MD Stony Brook Long Island Children’s Hospital.
Journal Club by Dr Mohammad Al-Busafi R4.  Compare efficacy of  Ibuprofen 10 mg /kg  Paracetamol and codeine ( cocodamol ! ) 1mg/kg (codeine component.
Lecture 17 (Oct 28,2004)1 Lecture 17: Prevention of bias in RCTs Statistical/analytic issues in RCTs –Measures of effect –Precision/hypothesis testing.
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
Research Skills Basic understanding of P values and Confidence limits CHE Level 5 March 2014 Sian Moss.
Evidence Based Medicine & Basic Critical Appraisal
How to Analyze Systematic Reviews: practical session Akbar Soltani.MD. Tehran University of Medical Sciences (TUMS) Shariati Hospital
Critiquing for Evidence-based Practice: Therapy or Prevention M8120 Columbia University Suzanne Bakken, RN, DNSc.
Scandinavian Simvastatin Survival Study (4S) The Lancet, Vol 344, November 19, 1994.
How to Analyze Therapy in the Medical Literature: practical session Akbar Soltani.MD. Tehran University of Medical Sciences (TUMS) Shariati Hospital
Tissue Plasminogen Activator for Acute Ischemic Stroke National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Understanding real research 4. Randomised controlled trials.
Measures of Association Professor Mobeen Iqbal Shifa College of Medicine.
EBCP. Random vs Systemic error Random error: errors in measurement that lead to measured values being inconsistent when repeated measures are taken. Ie:
CRITICAL APARAISAL OF A PAPER ON THERAPY PROF.JAMAL S.ALJARALLAH 1436(2014)
November 5, 2014 Matthew Tuck, MD Hospitalist, Veterans Affairs Medical Center Assistant Professor of Medicine, George Washington University.
SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.
Literature Appraisal Effectiveness of Therapy. Measures of treatment effect Statistical significance Odds ratio Relative risk Absolute risk reduction.
How to Analyze Therapy in the Medical Literature (part 1) Akbar Soltani. MD.MSc Tehran University of Medical Sciences (TUMS) Shariati Hospital
A Simple Method for Evaluating the Clinical Literature “PP-ICONS” approach Based on Robert J. Flaherty - Family Practice Management – 5/2004.
Risks & Odds Professor Kate O’Donnell. When talking about the chance of something happening, e.g. death, hip fracture, we can talk about: risk and relative.
This material was developed by Oregon Health & Science University, funded by the Department of Health and Human Services, Office of the National Coordinator.
Compliance Original Study Design Randomised Surgical care Medical care.
4S: Scandinavian Simvastatin Survival Study
Vanderbilt Sports Medicine Evidence-Base Medicine How to Practice and Teach EBM Chapter 5 : Therapy.
/ 161 Saudi Diploma in Family Medicine Center of Post Graduate Studies in Family Medicine EBM Therapy Articles Dr. Zekeriya Aktürk
EBM --- Journal Reading Presenter :林禹君 Date : 2005/10/26.
CRITICAL APARAISAL OF A PAPER ON THERAPY PROF.JAMAL S.ALJARALLAH.
CRITICAL APPARAISAL OF A PAPER ON THERAPY 421 CORSE EVIDENCE BASED MEDICINE (EBM)
Critical Appraisal Course for Emergency Medicine Trainees Module 3 Evaluation of a therapy.
Critical appraisals: Treatment. CLINICAL TRIAL = a prospective study comparing the effect and value of intervention(s) against a control in human beings.
Article Title Resident Name, MD SVCH6/13/2016 Journal Club.
CRITICAL APARAISAL OF A PAPER ON THERAPY PROF.JAMAL S.ALJARALLAH 1436(2015)
2 3 انواع مطالعات توصيفي (Descriptive) تحليلي (Analytic) مداخله اي (Interventional) مشاهده اي ( Observational ) كارآزمايي باليني كارآزمايي اجتماعي كارآزمايي.
Objectives (Chapter 20) Comparing two proportions  Comparing 2 independent samples  Confidence interval for 2 proportion  Large sample method  Plus.
EBM R1張舜凱.
CRITICAL APARAISAL OF A PAPER ON THERAPY
Evidence Based Journal Club: An Overview
Alcohol, Other Drugs, and Health: Current Evidence
Confidence Intervals and p-values
Alcohol, Other Drugs, and Health: Current Evidence
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
EVIDENCE BASED MEDICINE
The Anglo Scandinavian Cardiac Outcomes Trial
AIM HIGH Niacin plus Statin to prevent vascular events
Scandinavian Simvastatin Survival Study (4S)
Evidence Based Medicine How to Read a Paper About Therapy Results
Baseline characteristics of HPS participants by prior diabetes
Noninvasive Positive-Pressure Ventilation In COPD
Interpreting Basic Statistics
EBM – therapy Dr. Tina Dewi J , dr., SpOG
Associate Fellow, Centre for Evidence-based Medicine, Oxford
Basic statistics.
Presentation transcript:

How to Analyze Therapy in the Medical Literature (part 2) Akbar Soltani. MD. Tehran University of Medical Sciences (TUMS) Shariati Hospital www.soltaniebm.com

Three Step Guide in Using an Article to Assess Therapy Are the results of the study valid? What are the results? What measures of precision of effects were reported (CIs, p-values)? How can I apply these results to patient care?

Measuring Risk: Relative Risk Relative Risk (RR) = rate in exposed = 0.04 = 0.67 rate in nonexposed 0.06 SHEP. JAMA. 1991;265:3255-3264

Communicating risk: 40% RRR=? ARR=? 20% 20% 10% 10% 5% placebo

Measuring Risk: Relative Risk 6% 4% Relative Risk (RR) = rate in exposed = 0.04 = 0.67 rate in nonexposed 0.06 SHEP. JAMA. 1991;265:3255-3264

Measuring Risk: ARR? 6% 2% 4%

Measuring Risk: Absolute Risk Reduction Absolute Risk Reduction (ARR) is the absolute difference in event rates between the experimental and control patients. Calculated by: ARR = CER - EER = 0.06 - 0.04 = 0.02 In its decimal form the ARR is not easy to use! Converted to a percentage - there is an absolute risk reduction of 2%

Measuring Risk: RRR? 6% 2% 4%

Measuring Risk: Relative Risk Reduction Relative Risk Reduction (RRR) is the proportional reduction in event rates between the experimental and control patients. Two ways to calculate: RRR = (1 - RR) = (1 - 0.67) = 0.33 OR RRR = CER - EER = 0.06 - 0.04 = 0.33 CER 0.06 Therefore, treatment reduced the stroke rate by 33% OR a RRR of 33% means that the new treatment reduced the risk of death by 33% relative to that occurring among control patients CER = control event rate EER = experimental event rate

Usefulness of the ARR: Number Needed to Treat Number Needed to Treat (NNT) is the number of patients a clinician needs to treat in order to prevent one additional adverse outcome. NNT is for dichotomous outcomes. Calculated by: NNT = 1/ARR = 1/0.02 = 50 Therefore, you would have to treat 50 hypertensive patients to prevent one stroke.

Number Needed to Treat CER=0.06=100----------6 EER=0.04=100----------4 SO: 100-----------2 X------------1 50-----------1 Calculated by: NNT = 1/ARR = 1/0.02 = 50 Therefore, you would have to treat 50 hypertensive patients to prevent one stroke.

Why not just use RRR? PTH trial CER = 6 % Age =70 + 7 EER = 3 % ARR = CER – EER = 3% NNT = 1/ARR = 1/ 0.03 = 33 CER = 1/1000 Age = 55 + 5 EER = 1/2000 ARR=1/1000-1/2000=1/2000 NNT = 1/ARR= 2000

Why not just use RRR? RRR remains the same despite differences in absolute rate of events.

Why not just use RRR? ARRs reflect underlying susceptibility of patients and provides more complete information.

Why not just use RRR? NNTs provide a useful measure of the clinical effort that must be expended to avoid bad events.

Randomised trial of cholesterol lowering in 4,444 patients with CHD: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994: 344; 1383-1389 4,444 patients recruited as a sample inclusion criteria CHD and cholesterol 5.5 - 8 mmol/l exclusion criteria planned cardiac surgery, HF, child bearing potential simvastatin Vs. placebo double blind Outcomes mortality, major coronary events, admissions for acute CHD, incidence of revascularisation procedures

4S Study: self evaluation Median follow up 5.4 y analyse by intention to treat Significant reduction in all cause mortality 11.5% placebo Vs. 8.2% simvastatin ARR = RRR = NNT = patients with CHD and cholesterol 5.5 - 8 need to treated with simvastatin (20 mg) for 5.4 years to save one life

4S Study Cont’d Median follow up 5.4 y analyse by intention to treat Significant reduction in all cause mortality 11.5% placebo Vs. 8.2% simvastatin ARR = 11.5 - 8.2 = 3.3% RRR = (11.5 - 8.2)/11.5 = 29% NNT = 1/ARR = 30 30 patients with CHD and cholesterol 5.5 - 8 need to treated with simvastatin (20 mg) for 5.4 years to save one life

Why NNT is not enough NNT for continuous outcome is difficult to calculate Time can be added to calculations cautiously We can not compare NNTs from different studies easily Example: 2 RCT (Risedronate) 2 NNT! Can we say Risedronate is better than Risedronate!

Three Step Guide in Using an Article to Assess Therapy Are the results of the study valid? What are the results? What measures of precision of effects were reported (CIs, p-values)? How can I apply these results to patient care?

P Value or CI?

P Value or CI?

P Value or CI?

P Value or CI?

P Value or CI?

P Value or CI?

Confidence Intervals for Small Numerators Example: A new drug is given to 60 people. It seems to work, and has no serious adverse effects. The authors conclude it is "safe and effective." The upper limit for the 95% CI for any serious adverse effect is, or 5%. 95% confident of adverse event = 0/n – 3/n 3/60

Another example from textbooks! Based on one observational study in 94 women, no one report adverse reactions. Rule of 3: 3/94=upper limit of adverse effects that may not have been seen.

Three Step Guide in Using an Article to Assess Therapy Are the results of the study valid? What are the results? What measures of precision of effects were reported (CIs, p-values)? How can I apply these results to patient care?

How can I apply the results to patient care? Were the study patients similar to my patient? Were all clinically important outcomes considered? Are the likely treatment benefits worth the potential harm and costs?

Thank you!